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* 
CONTRACEPTION 
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Contraception is an important concept for sexually active 
adolescent females to understand who do not wish to become 
pregnant. This chapter reviews important, effective, and safe 
contraceptive methods that can be used by female youth. These 
methods include abstinence,  oral contraception,  contraceptive patch. 
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mini-pills, emergency contraceptives, injectable contraception 
(DMPA). implants (lmplanon), intravaginal ring, vaginal barrier 
contraceptives, intrauterine devices, and natural family planning. 
Promotion of se1rnal responsibility should be the charge of health 
professionals caring for adolescents and young adults. 
INTRODUCTION 
}. ,, 
An important issue for human beings is the acquisition of normal sexual 
healtl1, including the understanding and application of reproductive 
health when needed (1-5). Unfortunately, comprehensive sexuality 
education is not a topic provided to many of our children, adolescents or 
college students in the United States (5). The median age at first 
intercourse of 16 years in the United States is comparable to the age of 
coital initiation in other developed countries such as Canada, countries of 
Western Europe (France, Great Britain), countries of Eastern Europe and 
Eurasia (Russia) (6-11).  
Students who were sexually active in high school may continue to be 
at risk for pregnancy and sexually transmitted diseases in their college 
life; those youth who chose abstinence at one point may abandon this 
concept as they mature, choosing coital behavior with one or more 
partners in junior high school, high school, or college (8,12-14). There 
are over 15 million cases of sexually transmitted diseases in the United 
States, and over 60% of these occur in young people under 25 years of 
age) (4,7). 
All youth who are sexually active, including those with chronic 
illness, should be provided with appropriate contraceptive counselling 
and contraceptive prescription if they are not willing to accept abstinence 
(1,2,15-17). Since millions of female adolescents are sexually active, it is 
important that clinicians caring for them provide appropriate sexuality 
counselling, covering such topics as safe sex. contraception, and 
STD/AIDS prevention (12,18-21). Reasons for not using contraception 
include being abstinent, wishing to become pregnant, concluding they or 
their partners were sterile, fear of contraceptive "side effects" (such as 
breast        cancer        or         gain),         religious         objections          regarding 
contraception,  lack  of  clinician  education  about  contraceptives,  history  of 
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contraception or abortion, failure of insurance to cover contraception, 
and others (1,2,22-27). Approximately half of adolescent pregnancies 
occur within the first six months after the initiation of coital behaviour, 
while adolescents wait one year or more after starting coitus to seek 
advice from clinicians about effective contraception. Higher 
socioeconomic status and education are factors that lead to an increase in 
delay in coitus and willingness to use effective contraption if sexually 
active (28). Although adolescent pregnancy rates have dropped 33% in 
the United Sates from the early 1990s to 2003, the rates in the U.S. are 
the highest in developed countries with a birth rate in 15 to 19 year olds 
at 41.7/1 ,000 (14,29). 
A number of safe and effective contraceptive methods are available 
(1-4,15,18,20,30,31) (see table 1). The gap between efficacy of perfect 
use of contraceptives ( e.g., correct, consistent, and continued use of a 
chosen contraceptive method) and typical use leads to millions of 
unintended pregnancies each year (1,2,4,32-36). Efficacy rates of 
contraceptives are noted in table 2 (35,36). The barrier methods (i.e., 
condoms, diaphragms, cervical caps, vaginal sponges, female condoms, 
and vaginal spermicides) can be used quite effectively by motivated high 
school or college students who are taught how to use them; periodic 
abstinence has higher pregnancy rates, but is potentially an effective 
contraceptive method. The female's comfort for insertion of barrier 
methods is crucial for maximum contraceptive efficacy for these 
methods, and thus, they are not appropriate for many adolescent  who do 
not have this comfort level. 
Norplant, an effective method in which six progesterone capsules are 
inserted subcutaneously into the upper arm, was removed from the 
United States market in 2000. Implanon, a single progesterone rod 
implant, has now replaced Norplant in the Uniled States. The intrauterine 
device is an excellent contraceptive, but has been tainted with the image 
of inducing pelvic inflammatory disease ( 1,37). These contraceptive 
methods are discussed later in this discussion. 
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Table 1. Contraceptive methods 
Abstinence 
Combined Oral Contraceptives (COCs) 
Contraceptive patch 
Mini-pills (Progestin-only pills; POPs) 
Emergency contraceptives 
Injectable Contraceptives 
Depo-Provera® (Depo-medroxy-progesterone acetate 
Lunelle® (estradiol cypionate and medroxyprogesterone 
acetate) 
Implants 
Norplant I (withdrawn from the US market in 2000) 
Implanon ( one rod system with etonogestrel) 
Jadelle (Norplant II: two silastic rods with levonorgestrel) 
Intravaginal ring (NuvaRing) 
Intrauterine Devices 
Progestasert® IUD (with progesterone) 
ParaGard® (Copper T380A IUD) 
Mirena® (IUD with levonorgestrel) 
Vaginal barrier contraceptives 
Cervical cap (Prentif Cavity-rim®) 
Condoms (male) 
Contracepti ve sponge ( vaginal) 
Diaphragm 
Female condom (Reality®) 
Spermicides (vaginal) 
Sterilization (female sterilization, vasectomy) 
Physiological methods/natural family planning 
Coitus interruptus 
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Table 2. Efficacy of contraceptives (40,41) 
First Year Failure Rate 
Typical Use Perfect Use 
3-8 
0.6 
Contraceptive Efficacy 
Combined OCs 
Progesterone IUD
Copper T IUD 
Mirena IUD 
DMPA 
Norplant 0.05 
The choice of currently available contraceptive methods has 
increased considerably in recent years, offering females of reproductive 
age a variety of different methods that retlect their various needs and 
lifestyles. A number of contraceptive methods have received United
States Food and Drug Administration (FDA) approval over the past two 
decades (see table 3), including emergency contraceptives (Preven, Plan 
B), Depo-Provera (DMPA), the cervical cap, Lunelle (injectable 
contraceptive with estrogen), Mirena (an IUD with levonorgestrel), a 
contraceptive patch (Evra), an intravaginal ring (NuvaRing), and 
implants such as Implanon (28,38-40).  
Table 3. FDA approval history for contraceptives 
1. 12/90: Norplant (Withdrawn from US Market in 2000)
2. 10/92: Depo-Provera 
3. 9/98: Preven Kit
4. 7/99: Plan B
5. 10/00: Lunelle, "injectable pill" (withdrawn from the US Market)
6. 12/00: Mirena IUD 
7. 10/01: Nuva Ring (vaginal ring) 
8. 11/0l: Evra Patch 
9. 2006 Implanon (single rod) 
0.8
0.2
0.3
2
0.1
0.3
0.1
0.05 
1.5
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Technology has expanded over the past decade to include various 
ways of contraceptive steroid release (see table 4), leading to a number of 
potential advantages (see table 5). After OCPs were developed over 45 
years ago, the emphasis has been on having newer pill formulations with 
lower doses of estrogens as well as various progestins and developing 
phasic dosing regimens. Recently, newer delivery systems of hormones 
have been developed to help decrease contraceptive failure rates 
associated with incorrect use of contraceptives. For example, the patch 
and ring are user controlled and easy to discontinue. thus, being more 
appealing to some females (seetable4) (15,41).  
Table 4. Methods to deliver steroids 
Pills 
Patch 
Injectables 
Hormone-releasing IUDs 
Implants 
Vaginal rings  
Table 5. Advantages of new contraceptive methods 
Increases range of new contraceptive methods 
Very effective and easy to use 
Reversible, but not daily hormonal effects with better compliance 
Low hormone doses 
Continuous low hormone levels 
ORAL CONTRACEPTIVES 
One of the most popular contraceptive methods is the oral contraceptive 
pill (OCP) and there are over 145 brands of OCPs available worldwide; 
most OCPs contain both a synthetic estrogen and synthetic progestogen 
(see table 6) (l ,2,42). The estrogen is usually ethinyl estradiol (EE), but a 
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few brands contain mestranol. In general, it is thought that 30-35 mcg EE 
is equivalent to 50 mcg of mestranol (see table 6). There are many 
progestogens available, including norethindrone, levonorgestrel, 
gestodene, desogestrel, norgestimate, ciproterone acetate, and 
drospirenone. Drospirenone is a newer synthetic progestin chemically 
related to spironolactone (43). Estrogen may lead to nausea, headache, 
weight gain, breast tenderness, and breast enlargement; progestins may 
lead to unfavorable changes in low density lipoprotein (LDL) and high 
density lipoprotein (HDL) cholesterol, fatigue, depression, and menstrual 
changes. Questions to pose to the adolescent interested in oral 
contraceptives are listed in table 7. 
Table 6. Combined oral contraceptive hormones 
Estrogen 
Ethinyl Estradiol 
Mestranol (3 brands)
Progestins 
Norgestrel 
Norethindrone 
N orethindrone acetate 
Ethynodiol acetate 
Levonorgestrel 
Norgestimate 
Desogestrel 
Drospirenone 
Gesrodene: (not available in the US) 
Table 7. Questions to pose to teens requesting contraception 
1. What methods have you used before?
2. What are your worries about this method? 
3. What method do your friends use? What did they say about these 
methods? 
4. Do you think you can use this method correctly?
5. Do you worry about your weight? Are you dieting? 
6. Can you deal with unexpected bleeding?
7. Have you beard of some negative comments about OCP use
       (e.g., weight gain and infertility?)
8. Do you know the minor OCP side effects? 
9. Do you have any questions I have not answered?  
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OCPs prevent pregnancy by inhibiting ovulation, increasing cervical 
mucus viscosity, causing endometrial atrophy, and changing tubal 
transport mechanisms (1). Non-contraceptive benefits of the oral 
contraceptive are listed in table 8 (l,2,4,15,44). Most brands are 
manufactured as 21 or 28 day packs. The 21 day packs have seven days 
of placebo pills, so that the adolescent continues to take a pill each day of 
the cycle. Newer variations include brands which have only two placebo 
days in each 28 day cycle. Also available is an OCP dial pack dispenser, 
with each pill numbered and a dial that only turns in one direction. There is 
no combined oral contraceptive pill brand shown to be more effective 
than any other brand in preventing pregnancy; thus, any brand the female 
wishes to take to prevent unwanted pregnancy is acceptable (1,2,45). 
Some OCPs can be counterfeit and this possibility must be considered if 
pills are not obtained in pharmacies or other trusted places (46). Along 
with OCPs, condoms are also recommended to reduce the risk for 
sexually transmitted diseases (47,48). 
Table 8. Non-contraceptive benefits of combined oral 
contraceptives (1,2,4) 
1.    Treatment for dysmenorrhea 
2. Treatment for dysfunctional uterine bleeding 
3. Treatment for premenstrual syndrome 
4. Decreased risk for ovarian and endometrial cancer 
5. Decreased risk for symptomatic pelvic inflammatory disease
6. Treatment for polycystic ovary syndrome (PCOS) 
7. Treatment of acne vulgaris 
8. Treaunent for premature ovarian failure 
9. Treatment for endometriosis 
1O.   Treatment of hypothalamic amenorrhea due to eating disorders, exercise,  
stress 
11. Decreased Mittelschmei1z 
12. Prevention of ovarian cyst disease 
13. Lower incidence of ectopic pregnancy (reduced risk by 90%) 
14. Protective for rheumatoid arthritis 
15. Possible benefit in prevention/treatment of disorders associated with  
                  decreased bone mineral density 
16.        Possible benefit in the prevention of the development of leiomyomata 
uteri 
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Newer OCP brands now available include Alesse and Levlite (both 
with 20 mcg EE and 0.1 mg levonorgestrel), Apri (with 30 mcg EE and 
0.15 mg desogestrel), Desogen (30 mcg EE with 0.15 mg desogestrel), 
Estrostep (EE increasing from 20-35 mcgs over three weeks with 1 mg 
norethindone), Kariva (multiphasic with three levels of EE [20,0, 10] and 
0.15 mg desogestrel), and Mircette (multiphasic: three weeks of 20 mcgs 
of EE and 0.15 mg desogestrol, then 2 placebo pills. then 5 days of 1 O 
mcgs of EE alone). The two brands that are FDA-approved for treatment 
of acne vulgaris are Estrostep and Ortho Tri-Cyclen, Cyclessa is a low-
dose tripbasic OCP that contains less estrogen than Tri-Cyclen and other 
triphasic pills; it contains 25 mcg/day of ethinyl estradiol plus 
desogestrel [0.1, 0.125, and 0.15 mg/day] in each phase (49). 
Yasmin is an oral contraceptive with 30 mcg of EE and the 
progestin, drospirenone (43). This progestin is a synthetic version of 
progesterone as well as a spironolactone analog that can lead to 
potassium retention; 3 mg of drospirenone is equivalent to 25 mg of 
spironolactone. This OCP is contraindictced in females with renal, 
hepatic or adrenal insufficiency (43). It is unclear if this OCP has any 
advantages over other OCPs and its effect on acne is similar to other 
OCPs. One report notes 40 cases of VTB with 2 deaths in Europe in 
women taking Yasmin (50). 
Seasonale is an OCP with 30 mcg EE and 0.15 mg levonorgestrel 
(51). It provides continuous combined estrogen plus progestin for 84 
days followed by seven days of placebo, so that only four menses occur 
per year. Lybrel is another continuous use oral contraceptive that 
contains 0.09 mg of levonorgestrel and 0.02 mg of ethinyl estradiol. This 
extended cycling (e.g., absence of menses for several months) is 
especially helpful for adolescents who have medical problems that are 
worsened by menstruation or have significant adverse symptoms due to 
menstruation, such as dysmenorrhea or menorrhagia (see table 9) (52). 
However, extended cycling is associated with increased breakthrough 
bleeding, especially in the first year of use (51). Some females may be 
interested in extended cycling for life style reasons. For example, an 
athlete may wish to extend her cycle to avoid menses during athletic 
competitions or vacations. Extended cycling can be accomplished with 
any OCP by omitting the placebo pills and starting a new pack of OCPs 
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after 21. days. The Patch and NuvaRing have not been studied 
for extended or continuous use regimens. 
Table 9. Conditions that may benefit from extended cycling 
Dysmenorrhea 
Premenstrual Tension Syndrome (PTS) 
Menorrhagia
Iron Deficiency Anemia 
Endometriosis 
Headaches 
Epilepsy 
Rheumatoid Arthritis 
Coagulapathies 
Anticoagulation Therapy 
Contraindications to OCPS 
The World Health Organization (WHO) has published a list of medical 
eligibility guidelines to provide clinicians with guidelines for OCP use in 
those with various chronic illnesses that place users at increased risk of 
complications (see table 10) (49,53-56). Females in WHO category 1 
have no restrictions to use of the OCP, while females in category 2 have 
some increased medical risk. though pregnancy risks typically exceed 
OCP risks. Those in category 3 are typically not prescribed an OCP due 
to increased risks, unless pregnancy risk is high and there is no other 
method of contraception that is acceptable to the patient. If a condition 
places the female in category 4, the individual should not be placed on 
OCPs due to the high risks of significant OCP-induced adverse effects. 
Table 10. WHO medical eligibility categories for OCPs)*(56-58) 
Category one (no restrictions) 
Antibiotics 
Benign breast disease 
Contraception 
Benign ovarian tumors 
Cervical ectropion 
Dysmenorrhea, 
Endometriosis 
Epilepsy 
Family history of breast cancer 
Gestational trophoblastic disease (benign or malignant)  
Headaches (mild) 
History of ectopic pregnancy or abortion (postabortion after 
first or 
second trimester), 
History of gestational diabetes 
Increased STD risk 
Iron deficiency anemia 
Irregular menstrual bleeding 
Obesity 
Ovarian or endometrial cancer  
Past pelvic surgery 
Pelvic inflammatory disease 
Postpartum at or over 21 days 
Thyroid disorders (as hypo/hyperthyroidisrn, simple goiter) 
Varicose veins 
Various infections :malaria, tuberculosis, others) 
Sexually transmitted diseases  
Viral hepatitis carrier 
Category two (caution) 
Cervical cancer 
Diabetes mellitus (uncomplicated) 
Headaches (severe and if they start after beginning OCPs) 
Hypertension at 140-159/100-109 mm Hg  
Major surgery without prolonged immobilization 
Migraine headaches without focal neurologic involvement, 
Patients who have a hard time taking the OCP correctly: 
drug or alcohol abuse 
mental retardation  
persistent history as poor OCP takers 
severe psychiatric disorders 
Sickle cell disease or sickle C disease 
423 
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Undiagnosed breast mass 
Category three (usually OCP not given unless risks for pregnancy 
are higher than the OCP) 
Gallbladder disease 
Lactating (6 weeks to 6  months), 
Less than 21 days postpartum 
Medications that interfere with OCP efficacy 
Undiagnosed abnormal vaginal/uterine bleeding. 
Category Four (OCP contraindicated) 
Breast cancer 
Cerebrovascular accident (active or history) 
Complicated structural heart disease (with pulmonary hypertension, 
atrial 
fibrillation of history of subacute bacterial endocarditis) 
Coronary (or ischemic) heart disease (active or history) 
Deep vein thrombosis or pulmonary embolism (active of history) 
Diabetes mellitus (complicated with retinopathy, neuropathy, 
nephropathy) 
Headaches (including migraine headaches) with focal 
neurologic symptoms 
Hypertension (severe: (160+/110+ mm Hg or with vascular 
complications) 
Lactation under 6 weeks postpartum 
Liver disease (including liver cancer, benign hepatic 
adenoma, active viral 
hepatitis, severe cirrhosis) 
Pregnancy, complicated 
Surgery (involving the lower extremities and/or prolonged  
immobilization 
*(World Health Organization, 1996, 2000; Pettinato, 2003) 
Patel DR. Pratt HD, Bhave S, eds. Course manual for adolescent health. 
2002:309-24. 
*Used with permission from Greydanus DE.  Contraception.  ID :  Greydanus DE, 
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CARDIOVASCULAR RISKS AND OCPs 
Research has indicated an increased risk of cardiovascular 
complications in females on OCPs (50,57-68). Obese and non-obese 
females on birth control pills have an increased risk for pulmonary 
emboli, thrombophlebitis, and vascular thromboses. Some studies note a 
greater incidence of myocardial infarction and subarachnoid hemorrhage 
as well (50). An absolute OCP contraindication is a past history of 
venous thrombosis (VT) and the risk of VT is more significant for the 
adolescent or young adult than arterial thrombosis. Significant obesity is 
a VT risk factor and the risk is increased in obese OCP users (58-60). 
Table 11 notes risk factors for thrombosis. In 2008 the US Food and 
Drug Administration (FDA) added a label to the birth control patch that 
patch users were at higher risk for venous thromboembolism than OCP 
users, since patch users are exposed to higher estrogen levels than noted 
with OCP users. 
Table 11. Causes of thromboses 
Factor V Leiden mutation 
Prothrombin mutation G20210A 
Protein S Deficiency 
Protein C Deficie1tcy 
Antthrombin III deficiency 
Hyperhomocysteinemia from mutations in MTHFR gene 
Deficiencies of Proteins: C, S, and antithrombin III 
Tobacco use 
Other medical risk factors: immobilization, surgery, severe illness 
Others: cancer or pregnancy 
Cardiovascular deaths from venous and arterial complications in 
non-smoking females aged 20-24 years is 2-6 per million per year (57). 
There is a 3-6 fold increased lisle factor for VT development in OCP 
users and the risk for VT is higher with desogestrel versus levonorgestrel 
(15,57, 61). The VT risk in the general population is 4 per 100,000 
women per year, 10-30 for those on OCPs, and 60 for females who are 
pregnant or postpartum (57,62-64) (see table 12). Most individuals who 
,. ' ' 
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develop venous thrombosis do not have identified VT risk factors (see 
table 11).  
Table 12. Rate of non-fatal tbromboembolism in females (57,62-64) 
1. No risk conditions: 4/100,000
2. Low-dose OCPS: 10-30/100,000 
a. 10-15: on norgestimate or levonorgestrel OCP 
b. 20-30 on desogestrel OCP 
3. Pregnancy: 60/100,000 
4. Factor V Leiden mutation: 140 if on the OCP (32 if not on the OCP)
Table 13 lists screening questions to use when considering OCPs for 
contraception. In general, if there is no overt positive family history for 
VT in those under 50 years of age, one does not need to screen for factor  
V Leiden or other prothrombotic mutations because of lack of cost-
effectiveness. However, the Factor V Leiden mutation is the most 
common genetic cause of thrombophilia, with a prevalence of 3.6% in 
asymptomatic women, and 23% among Caucasian women with first 
episode of spontaneous venous thromboembolism. Factor V Leiden 
accounts for up to 20% of first-time VT-this prothrombin mutation 
leads to a 2-4 times increased risk for VT. Thus, the OCP and the patch 
should not be used if there is a history of thromboembolism. The mini- 
pill (progestin-only) can be used in this situation. Other contraceptives 
that can also be used include Dcpo-Provera, Mirena IUD, and barrier 
methods.  
Table 13. Questions about personal/family history 
of thromboembolism 
1. Have you or a close family member (FM) (including uncles/aunts) 
have blood clots in legs or lungs? 
2. Have you/close. FM been hosp. for blood clots in legs/lungs? 
3. Have you or FM taken blood thinner? 
4. Under what circumstances did the clot form:
Cancer 
Obesity 
Airline travel 
Immobility 
Pregnancy 
Others
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Congenital heart disease 
The concern with, using OCPs in those with congenital heart disease is 
that complications may arise because of increased risk for 
thromboembolism (TE) and endocarditis. Increased risk for TE is due to 
increased circulation of clotting factors from estrogen because of 
stimulation of serum globulins from the liver. OCPs and the patch are 
contraindicated in cardiac conditions with cardiac shunts, congestive 
heart failure, low output cardiac disorders, and coronary heart disease 
(62,65-68). The OCP and patch should be avoided in those with cyanotic 
heart disease and pulmonary hypertension. 
Progestin-only contraceptive methods are acceptable for most 
females with congenital heart diseases including the mini-pill and Depo-
Provera (DMPA) if the patient is stable; these patients typically are on 
anticoagulation as well. The Mirena intrauterine device (IUD) and barrier 
contraception are safe as well in these situations. Patients with valvular 
heart disease and congenital heart disease are at risk for endocarditis for 
one month or so with and after an IUD placement. Other IUD 
complications at the time of IUD placement include bradycardia, 
seizures, and syncope; the IUD is contraindicated if the female is on 
anticoagulation, since there is increased risk of bleeding with the IUD 
placement. These contraceptive methods are reviewed later in this 
discussion. 
Hypertension 
There is a small increase in blood pressure on the OCP with a 6-8 mm 
Hg rise in the systolic pressure and a 4-6 m.m Hg is the diastolic 
pressure. Blood pressure should be monitored on the OCP and a low-
dose OCP is acceptable for stable hypertension with no end organ disease 
(67). OCPs are contraindicated in those with severe hypertension (i.e., 
systolic blood pressure > 160 mm Hg and/or diastolic blood pressure 
>100 mm Hg) (67). The risk of ischemic complications is probably 
slightly increased in patients with hypertension on OCPs; the US studies 
suggest no risk, while European studies note some increased risk  (65-68). 
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Other contraceptives that are safe for patients with hypertension are  
Depo-Provera, the Mirena IUD, and barrier methods. 
Hyperlipidemia 
Estrogen can worsen lipid patterns (increase low density lipoproteins 
[LDL] and decrease high density lipoproteins) to increase risks for 
coronary artery disease (CAD) risks; estrogen can also increase 
triglycerides, but not to worsen CAD risks (66). Low-dose OCPs are safe 
for stable hyperlipidemia but should be avoided when the LDL is over 
160 mg/dl, triglycerides are over 250 mg/dl, or when multiple CAD risk 
factors are present (65,66,68). These CAD risk factors include smoking, 
obesity, diabetes mellitus, hypertension, and positive family history for 
premature CAD (1,2,4). Progestin-only contraception are safe with 
hyperlipdemia.  
Obesity 
Sexually active obese teens who do not want to become pregnant also 
need contraception. Research notes that overweight/obese youth use 
contraception less than their normal weight peers and obese females have 
reduced efficacy with OCPs as well as the patch because of higher 
adipose tissue sequestration, increased enzyme metabolism in the liver, 
and higher basal metabolic rates (60,69). However, OCP efficacy in 
obese females is higher than that noted with the use of barrier 
contraception. OCPs can be a good contraceptive option for females with 
obesity, polycystic ovary syndrome, acne, and hirsutism (44). In 
addition, adverse pregnancy outcomes in Ibis group must be taken under 
consideration (58,59, 70-72). VT risks are increased in obese females and 
progestin-only contraception (i.e., the mini-pill and Depo-Provera) can 
be safely used. However, there can be increased weight gain and central 
redistribution of adipose tissue following use of Depo-Provera. Also 
effective in obese individuals are the intravaginal ring and the IUD. In 
conclusion, the safest methods of contraception for obese female adults 
may be the mini-pill and the levonorgestrel IUD (58). 
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Diabetes mellitus 
Research notes that OCPs are safe and effective in females with well-
controlled diabetes mellitus (types 1 and 2) who do not have such 
diabetic complications as retinopathy, nephropathy, or peripheral 
vascular disease (58,60). Metabolic status in diabetes is not worsened on 
OCPs or the patch and the newer progestins (i.e., desogestrel, 
norgestimate, or gestodene) may effect metabolism of carbohydrates less 
than older progestins (66). OCPs should not be provided if there is a 
history of VT, diabetic complications, or hypertension (58.60). Other 
safe methods of contraception for diabetic youth include the IUD and the 
mini-pill (59). If an IUD is placed in a diabetic youth, there may be an 
increase in recurrent vaginal yeast infections that are resistant to standard 
anti-fungal management. Depo-Provera is safe and effective in those 
with diabetes, including when diabetic complications are present (65,66). 
Thyroid disease  
All contraception should be safe and effective in those with hyper- or 
hypothyroidism; however, if the you1h is on levothyroxine for 
hypothyroidism, check T4 and TSH levels after two cycles of OCPs 
(65,66). 
Hyperprolactinemia 
If pituitary adenoma is not the cause, OCPs are safe and also helpful to 
prevent further bone loss and provide effective concraception (65). 
Migraine headaches 
Migraine association with menses (catamenial headaches) may be due to 
reduced estrogen levels at menses (65). OCPs are not contraindicated in 
tension or muscular-type headaches, though the OCP should be stopped 
if the female presents with severe, worsening headaches after slatting  the 
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OCP. Caution is recommended in using OCPs in females with a histo1y 
of migraine headaches. OCPs should be stopped or avoided in those with 
migraines that worsen on OCPs or in those with migraines complicated 
by neurological features (i.e., auras) (1,2). 
Those with migraines and neurological symptoms (i.e., complicated 
migraines) have an increase risk for cerebral ischemia and 
cerebrovascular accidents (CVAs) on the OCP because of the estrogen 
component (73). Studies in Europe noted a four fold increase in ischemic 
strokes in females with complicated migraines on the OCP while studies 
in the United States suggest a two-fold increase (66). The risk of 
thrombotic stroke in migrainoid females on OCPs is 8 per 100,000 at age 
20 years versus 80 at age 40 years of age (66). 
In summary, OCPs should not be given to those with severe 
migraines or complicated migraines, including those with hemiplegic or 
ophthalmoplegic types. Stop the pill if the headaches worsen in OCPs. 
Those with focal neurologic features (i.e., hemiplegic or ophthalmoplegic 
types) are given a WHO category of 4 (contraindication), because of the 
high risk for CVAs on OCPs. 1f headaches without focal neurologic 
features start after the OCP has begun, a WHO category of 2 is given. If 
complex migraines are present, avoid estrogen and consider Depo-
Provera, the mini-pill, or the Mirena IUD in addition to barrier 
contraceptives (58,59). 
Epilepsy 
One million females of child-bearing age have a seizure disorder and 
may have reduced efficacy if  placed on certain anti-epileptic medications 
(74-77). Catamenial epilepsy may occur because of hormonal changes 
that occur during the menstrual cycle (77). Estrogen has proconvulsant 
effects and progestin has anti-convulsaut effects (74-76). Puberty itself 
does not usually worsen or improve epilepsy of childhood, though 
juvenile myoclonic epilepsy may develop as puberty ensues (77). 
However, if seizure activity does worsen with puberty, an adjustment in 
anti-seizure medications usually corrects the situation. Ethinyl estradiol 
undergoes considerable first-pass metabolism as noted in table 14 while 
the metabolism of progestins in summarized in table 15. 
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Table 14. Metabolism of ethinyl estradiol 
1. In the Gastrointestinal tract by sulfation
2. In the liver by glucuronidation or hydroxylation
a. Enzyme CYP3A4 is 1 of 7 primary isoenzymes of the P-450 
enzyme system 
b. CYP3A4 catalyzes the hydroxylation
3. Metabolites under conjugation and enterohepatic recirculation
(results in reabsorption of active EE) 
4. Extent of enzyme induction varies depending on genetic+
environmental factors
Table 15. Metabolism of progestin 
1. Synthetic progestins are eliminated through hepatic metabolism.
2. Progestins do not undergo extensive first-pass metabolism or 
enterohepatic recirculation
3. CYP3A4 isozyme is involved in progestin metabolism
4. Inducer anti-epileptic medications ↑ sex hormone-binding 
globulins that ↓ P
5. Levels
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However, many antiepileptic dmgs (AEDs) can induce an increase in 
hepatic microsomal enzymes (cytochrome P-450 system), which can 
produce increased pill metabolism and decreased pill hormone 
concentrations. The result is a decrease in the pill's contraceptive ability 
(increased estrogen [E] metabolism, increased progestin [P] protein 
binding, decreased E & P concentration with decreased contraceptive 
efficacy) (76), resulting in an estimated 3.1 pregnancies per 100 women 
years of use; this pregnancy rate can be significant when considering the 
potential teratogenic effects of AEOs on the developing embryo (74-76). 
Hepatic enzyme inducer anti-epileptic drugs are listed in table 16.  
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Table 16. Inducer anti-convulsant medicatations (1,57,63,72, 74) 
Phenytoin (Dilantin) 
Phenobarbital 
Primidone (Mysoline) 
Felbamate (mild inducer) (Felbato) 
Carbamazepine (Tegretol) 
Oxycarbazepine (mild inducer) (Trilepal) 
Topiramate (mild inducer) (Topamax) 
Tiagabine 
Newer AEDs have minimal interaction with OCPs. Table 17 lists 
anti-epileptic drugs (AEDs) that do not cause such interference because 
they do not inhibit hepatic microsomal enzymes; they include valproic 
acid (Depakote) and zonisamide (weak inhibitor [Zonegran]) and those 
with no effect on P-450 enzymes and no decrease in estrogen or 
progestin levels. Use of OCPs and lamotrigine may reduce lamotrigine 
levels and close monitoring is recommended (74-76). There can also be 
drug interference in those taking AEDs, OCPs., and other drugs that are 
metabolized via the P-450 pathway, that affect drug concentrations; these 
include ketoconazole, fluoxetine, erythromycin, propoxyphene, others. 
AEDs have various side effects including increased sexual dysfunction, 
irregular menses, and ovulatory failure. For example, valproate has 
increased risks for anovulation, polycystic ovarian syndrome, polycystic-
appearing ovaries, and hyperinsulinemia.  
Table 17. AEDs that do not effect OCP hormonal levels 
(1,57,63,72, 74) 
Gabapentin (Neurontin) 
Ethosuximide (Z rontin) 
Tiagabine 
Lamotrigine(Lamietal) 
Levetiracetam (Keppra) 
Pregabalin 
Vigabacrin (Sabril) 
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Management: Epilepsy and OCPs 
Some clinicians conclude that the contraceptive efficacy of inducer 
AEDs with OCPs is acceptable and use these AEDs along with the OCP. 
Some clinicians seek to avoid such interference by prescribing higher 
estrogen OCPs (i.e, 50 mcg to 100 mcg ethinyl estradiol) when patients 
are taking inducer AEDs, while other clinicians increase the frequency of 
OCP closing and reduce the pill-free interval of seven days along with 
adding barrier contraception (74-76). A more potent progestin may be 
used if break-through bleeding occurs. As noted, anti-epileptic drugs do 
have a teratogenic potential and thus, these patients should take folate to 
lower the risk for neural tube defects, while also taking calcium and 
vitamin D supplementation to lower risks for AED-induced bone disease 
(78). 
The amount of AEDs can be altered during the menstrual cycle to 
reduce side effects. For example, chose with reduction of the AED during 
the OCP placebo week may experience reduced drug-induced headaches 
(66). The mini-pill has reduced contraceptive efficacy in those on AEDs, 
due to low progestin levels and is not recommended. However, Depo-
Provera is effective and may have anti-convulsant effects, though it has 
not been studied in this regard. The IUD (Mirena and copper) and barrier 
contraception are also recommended in patients on inducer AEDs that 
need contraception. 
Arteriovenous malformation (A VM) with epilepsy 
There is no increase in a hemorrhagic complication in those with an 
AVM and epilepsy during pregnancy or labor, if the AVM has been 
surgically treated. There is no research that the OCP will increase 
thrombosis in a patient with an A VM on an OCP (79). An AVM in the 
gastrointestinal tract may have reduced bleeding risks on OCPs (79). 
Liver disorders 
Estrogen and nor-progestins are metabolized in the liver and alter 
hepatocellular function, leading to increase in cholesterol, reduction in 
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bile acid as well as bile secretion, and changes in bile composition. OCPs 
should not be provided for those with active liver disease (WHO 
category 4), including cirrhosis and hepatitis (65).The OCP or patch can 
be used if liver function returns to normal, though the effect of obesity-
related NASH (nonalcoholic steatohcpatitis) on OCPs is not clear at this 
lime. Depo-Provera is acceptable unless there is increased risk for 
bleeding, while barrier contraception and the Mirena IUD are acceptable 
contraceptive methods if active liver disorders are present. The birth 
control pill-associated hepatic cell adenoma has an estimated annual 
incidence of 3.4 cases per 100,000 pill users. A variant of this benign 
tumor is the focal nodular hyperplasia; on rare occasions this lesion can 
rupture in the liver or peritoneum, causing a syndrome of right upper 
quadrant mass, abdominal pain, right shoulder pain, and diverse 
symptomatology associated with acute blood loss (1,2). 
Renal disease 
Pregnancy can worsen renal prognosis in those with end-stage renal 
disease (ESRD) who are not on dialysis and those who are post-
transplant. OCPs are safe and effective for females with ESRD, if the 
renal condition is stable and there is no unpaired renal function, 
hypertension, cardiovascular disease, or thromboembolism (65,66). 
Systemic lupus erythematosus is considered below. In those with stable 
renal disease, acceptable contraceptive methods include OCPs, the patch, 
Depo-Provera, the Mirena IUD, and barrier contraceptives. OCPs are 
useful for stable renal disease without complications and are beneficial to 
control the hype1menorrbea often seen with chronic renal disease. 
Estrogen should be avoided in those with chronic renal disease who have 
significant hypertension or are bed-ridden; alternative contraceptives in 
such situations include progestin-only methods or the Mirena IUD. The 
IUD should be avoided in those with risk of infections (i.e., endometritis) 
and with worsening anemia. 
There is limited research at this point to guide decisions regarding 
contraception for sexually active renal transplant females. The 
medications that the renal transplant patient takes should be considered, 
as  well  as  the  specific  complications   when   advising   on   specific 
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contraceptive methods (80). Those on estrogen contraceptive methods 
should be carefully monitored, while Depo-Provera and banier methods 
seem to be safe. Use of IUDs may cause complications, since these 
females are on immunosuppressive medications and are 
imo1uoocompromised because of their chronic renal disease. IUDs 
should be avoided in those on peritoneal dialysis because of the risk of 
peritonitis with run insertion; if the IUD is inserted, prophylactic 
antibiotics should be prescribed (80,81).  
Pulmonary disorders 
Some adolescent females with cystic fibrosis are fertile and are at risk for 
pregnancy if sexually active. Thus, contraception is appropriate to 
discuss with sexually active females who have cystic fibrosis. The 
concern is that the progestin in OCPs may thicken bronchial mucus as it 
does cervical mucus. However. interference with contraceptive efficacy 
has not been observed and progestin is not contraindicated in those with 
cystic fibrosis (82). Pulmonary embolism is a rare complication of OCPs, 
as noted before. The Mirena IUD and barrier contraceptives are safe for 
those with cystic fibrosis (65). Also, there is no OCP contraindication for 
females with asthma. Patients with tuberculosis who are placed on anti- 
tuberculosis therapy, such as rifampin, will have reduced OCP 
effectiveness. 
Inflammatory bowel disease 
Menstruation can worsen inflammatory bowel disease (IBD) symptoms 
because of menstrual-induced rise in prostaglandin levels that can worsen 
contractions of the uterine and gastrointestinal muscles. Pregnancy is not 
very common in females with inflammato1y bowel disease (IBD), and 
can worsen the IBD condition. OCPs can reduce gastrointestinal 
symptoms in IBD if taken with active colitis; however, there can be 
limited OCP absorption with less pill effectiveness and increased break-
through bleeding in this situation. However, contraception should be 
provided to sexually active females with  IBD (83).  Thus, the  patch may 
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be best to avoid the need for gastrointestinal absorption. Depo-Provera is 
effective and can be useful to reduce the incidence of menstrua1 bleeding 
and subsequent anemia. Depo-Provera may be recommended in the small 
percent of cases in which there is concomitant IBD and a coagulation 
disorder. Bone density issues should be taken under consideration, 
especially if corticosteroid therapy is administered. Barrier contraceptive 
methods are safe for those with IBO who need contraception. The 
Mirena IUD should be safe though research is needed to further su1dy its use 
in those with IBD. 
Cancer 
OCPs are absolutely contraindicated in females with breast cancer, 
though they may reduce the risk for ovarian and endometrial carcinoma 
(1,2,84). However, estrogen and progestin receptors are found in ovarian 
cancer tissue and OCPs arc avoided with ovarian cancer. 
Cancer treatment: Chemotherapy and radiotherapy 
If   thrombocytopenia (TCP) is  present,  OCPs are effective and beneficial  
to stop TCP-induced bleeding. Continuous OCP use is helpful, while 
cyclic OCPs should be avoided for severe or prolonged TCP. OCP 
absorption is reduced if there is emesis or mucositis. OCPs should be 
avoided if severe gastrointestinal side effects develop. For example, the 
gastrointestinal flora may  change  as  a result of treatment-induced 
diarrheal cycles. The presence of infections or antibiotic use alter gastro-
hepatic circulation that can result in reduced OCP effectiveness. The 
OCP should be avoided in those with a history of thrombosis, as noted 
earlier. 
Drug interactions may affect OCP use, as for example, with rifampin 
or rifabutin that can decrease OCP levels. Also, OCPs can reduce drug 
clearance, as, for example, noted with prednisolone. Careful monitoring 
is needed if cyclosporine is used, while OCPs should be avoided in those 
receiving allogenic bone marrow transplants taking cyclosporine and 
prednisolone in order to prevent the development of graft-versus-host 
disease and graft rejection. 
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Other contraceptives in cancer patients
The mini-pill is the first choice of contraception if the patient is receiving 
chemotherapy; ii should be avoided with a positive history of an ectopic 
pregnancy and if the patient is taking certain medications such as 
griscofulvin, rifampicin, or some anti-convulsant drugs. If there is active 
vomiting or mucositis, OCP absorption may not occur. Depo-Provera is 
not given if chemotherapy occurs due to the potential occurrence of 
infection with blood cell changes (i.e., neutropenia or thrombocytopenia 
[TCP]) or the occurrence of hematoma with an injection. Depo-Provera 
may worsen bone loss already noted in some receiving chemotherapy. 
Contraceptive implants can cause complications in those with TCP and 
irregular bleeding, while these potential difficulties can be acceptable if the 
patient is stable and only brief or transient TCP occurs. The IUD should be 
avoided in females with neutropenia and a TCP. 
HIV 
Drug interactions may occur between HIV medications and OCPs. For 
example, some HIV medications (as efavirenz or atazanavir) increase 
ethinyl estradiol, while others (nevirapine and lopinavir/ritonavir) 
decrease estrogen (59,85). Depo-Provera is effective in females with HIV 
and there is minimal interaction with HIV medications,  such as 
nelfinavir, efavirenz, nevirapine or nucleoside analogues (85,86).  The 
IUD is also effective and safe in patients with HIV. 
Rheumatological disorders (RD) 
The use of OCPs is problematic in females with rheurnacologic disorders 
(RD) because of the concern with the risk of thrombosis and 
potential RD exacerbations. These risks are worsened with the amount of 
ethinyl estradiol and progestin type (87). Research suggests that there is 
no worsening of systemic lupus erythematosus (SLE) or increased SLE 
flare ups if these females are taking OCPs and the patient has stable SLE (87). 
There may be drug interactions between RD medications and OCPs. 
Estrogen-containing   contraceptives  should   be   avoided   in  those  with 
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antiphospholipid antibody (aPL) syndrome because of an increased risk 
for thrombosis, as noted below. Progestin-only contraception should be 
used in those with aPL syndrome if a reduction in menstrual bleeding is 
needed (as with Depo-Provera) and if the patient needs anticoagulation. 
Antiphospholipid-antibody (aPL) syndrome 
Thrombosis is increased in aPL syndrome, especially if there are 
additional risk factors, as noted in table 11. The SELENA study (Safety 
of Estrogen in Lupus Erythematosus National Assessment) concludes 
that OCPs should be avoided in patients with aPL syndrome who have 
moderate or high titers of antiphospholipid antibodies (i.e., at or over 40 
GPL or MPL units); progestin-ooly contraception should be used and 
Depo-Provera is an acceptable contraceptive agent (87). The Mirena IUD 
is also acceptable for those with the aPL syndrome. 
SLE (systemic lupus erythematosus)  
There is no increase in SLE exacerbations in females with stable SLE 
who ate placed on OCPs and thus, OCPs are used for contraception in 
these females (66,87,88). Patients with SLE should be screened for aPL 
syndrome and the estrogen avoided if there is aPL syndrome, vasculitis, 
or nephritis (88). More research is needed regarding use of the OCP 
patch, but increased hormone levels are noted and thus, the patch should 
be avoided if the OCP is contraindicated. Drospirenone (as noted in 
Yasmin) can lead to hyperkalemia and is avoided in renal insufficiency. 
The mini-pill and barrier contraception are acceptable for those with 
SLE, while Depo-Provera is avoided because of bone loss issues 
associated with this contraceptive. An IUD may lead to increased risk for 
infection in SLE patients because of decreased immunity, though more 
research is needed in this regard. 
.  ·. 
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Rheumatoid arthritis (RA) 
OCPs and the contraceptive patch have not been shown by most research 
to increase RA exacerbations, but neither do they do improve RA (87). 
Androgenic OCPs with second generation pills might be best to 
maximize androgenic immunosuppression. Females with severe RA 
might have problems with insertion of diaphragms or vaginal rings. 
Though research is limited, it is best to avoid IUDs for females with RA 
who are taking immunosuppressivc medications, because of potential 
infection risk. The use of barrier contraception or the TUD may also be 
physically difficult in some RA patients. 
The use of OCPs has not been shown to increase exacerbations of 
Raynaud's disease. However, OCPs shot d be avoided if there is risk of 
ischemia, atherosclerosis, or vasc11litis. There may be d111g interactions 
between OCPs and RA drugs, such as corticosteroids, warfarin, 
cyclosporin, and certain anticonvulsants. OCPs. the patch, and the 
vaginal ring should be avoided in RA females with prolonged 
immobilization and the OCP should be stopped before surgery; the 
timing is varied and ranges from two weeks to two months before 
planned surgery, due to negative effects of estrogen on  coagulation. 
Some clinicians perioperatively add heparin in such cases, in order to 
reduce the risk for venous thrombosis (VT), particularly if there are other 
VT risk factors present. Others add a progestin-only contraceptive 
method when estrogen is stopped. Some clinicians have used Depo-
Provera once before surgery if contraception is needed . 
Sickle cell disorders (SCD) 
Pregnancy increases risks for both the mother with SCD and fetus and 
thus, contraception is important for sexually active females with SCD 
who do not wish to become pregnant. Since the phenomenon of sickling in 
SCD is not a process of thrombosis, there is no known increased 
thrombosis risk in females with SCD in OCPs; thus,  OCPs should be 
safe for these females, though research is limited in this regard. In 
addition to effective contraception. limited research suggests that Depo-
Provera  may  reduce  sickling in  SCD  and may be  the best method  of 
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contraception for females with SCD [1,65]. Barrier contraceptives 
are also safe in females with SCD. 
Intellectual disability (mental retardation) 
OCPs, the patch, and ba1Tier contraception may be difficult to use 
because of limited cognitive skills in sexually active females with 
intellectual disability (16,65,66). The most popular method is Depo-
Provera, though the issue of osteopenia should be monitored in these 
female adolescents. The intrauterine device bas been used as well 
(89,90). Sterilization remains a controversial issue in adolescent females 
with mental retardation. 
Schizophrenia 
It is difficult for females with schizophrenia to take OCPs daily or use 
the patch effectively; worsened moodiness may occur on some taking 
oral contraception. The IUD may become a delusional focus for some 
schizophrenic females and it can be very difficult to recognize JUD. 
induced infection when the patient is delusional (91}. The best 
contraceptive method for sexually active females with schizophrenia may 
be Depo-Provera. 
Drug interactions 
Clinicians should review any other medications patients on OCPs a.re 
taking. in order to consider possible drug interactions (see table 18) 
(74,92). For example, antacids (aluminum and magnesium types) prevent 
gastrointestinal absorption of OCPs, especially the progestin component; 
thus, ingestion of OCPs and antacids should be separated by at least three 
hours. Broad spectrum antibiotics do not interfere with OCPs, though 
previous anecdotal reports suggested the opposite (1,2). However, 
interference is noted with some drugs, such as rifampin, griseofulvin, 
ketoconazole, and itraconazole. Serum levels of some medications can be 
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affected if the patient is on  OCPs, such as tricyclic antidepressants, 
cyclosporine, caffeine, theophylline, and prednisolone. Warfarin levels 
may be increased or decreased,  while free thyroxine levels are reduced 
on OCPs due to increased levels of thyroxine binding globulin.   
Table 18. Potential drugs interactions with OCPs (92) 
I. Potent hepatic enzyme inducer with decreased contraceptive
efficacy
a. Rifampin
b. G1iseofulvin
c. Ketoconazole; itraconazole
II. Hepatic enzyme inducer w/o evidence of reduced efficacy 
a. Phenobarbital
b. Phenytoin 
c. Carbamazepine
d. Primidone
e. Elhosuximide
III. Meds that reduce EE levels with increased breakthrough bleeding 
(BTB); no decreased 
efficacy 
a. Tricyclic antidepressants
b. Chlordiazcpoxide; diazepam 
c. Theophylline 
4. Other Reported Drug Interactions with COCs*
a. Aspirin; acetaminophen 
    1) Increased clearance of these meds if COCs added  
2) Anedotal (not proven) rec: increase med doses
b. St. John's wort 
       1) lnhibitor of P450 isoenzymes  
2) Increased breakthrough bleeding
3) Anecdotal evidence of reduced OC efficacy
*Glasier A: Drug interactions and combination oral contraceptives. Dialogues  
       in Contraception (Univ. So. CA) 6(5): 1-4, 2000 (http://dialogues.usc.edu)
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As previously noted, a number of minor side effects may occur with 
OCP use including nausea, headaches, mood changes, and breast 
tenderness; these adverse effects can be quite troublesome to adolescent 
females (1 ,2, 31). These often disappear with increasing duration of OCP 
use. Although many women feel that OCPs are associated with weight 
gain, there is no convincing evidence that OCPs cause an increase in 
weight (1,2). Breakthrough bleeding (BTB) is a common side effect of 
OCP use and one of the most frequent reasons for OCP discontinuation. 
In most patients, BTB decreases with consistent continued use, and there 
is no need to change OCP brands because of this side effect. However, if 
BTB is severe and/or unrelenting, switching to an OCP containing 
norgestrel (e.g., Lo/Ovral®), norgestimate (e.g., Ortho-Cyclen®) or 
levonorgestrel (e.g., Nordette®, Triphasil®) may be helpful. One can 
also recommend taking two pills a day until the bleeding stops or adding 
20 mcg of ethinyl estradiol for 7-10 days. It is rare that a pill with 50 mcg 
of ethinyl estradiol is needed to control such bleeding. 
TRANSDERMAL HORMONAL CONTRACEPTION 
Use of transdermal mechanisms for delivery of medication became 
available in the early 1980s. Medications that are now available in 
transdermal formulations include clonidine, estradiol, fentanyl, nicotine, 
nitroglycerin, scopolamine, and testosterone (93-95). The FDA approved 
the first transdermal contraceptive patch (Ortho Evra Patch) in November 
of 2001. It has similar side effects as OCPs with the addition of mild to 
moderate application site reactions and increased incidence of breast 
symptoms and dysmenorrhea (95-101). It is not yet clear if the patch 
offers any significant increase in efficacy or safety advantages over 
OCPs (95). However, this method may improve compliance in some 
women. 
The contraceptive patch is a matchbook size device placed on the 
skin (abdomen, upper outer arm, buttocks, upper torso [not the breasts]). 
It consists of a three-layer matrix with an outer polyester protective layer 
(light tan in color), a middle layer that contains adhesive as well as 
Miscellaneous 
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contraceptive steroids, and an inner, clear polyester liner that is removed 
before skin application (96,97). The patch results in a daily hormone 
release of 20 mcg ethinyl estradiol and 150 mcg of norelgestromin, the 
primary active metabolite of norgestimate (94,98-104). The hormones are 
rapidly absorbed into the blood and a steady state is reached in two days, 
similar to that noted with the oral contraceptive Ortho-Cyclen. The patch is 
started on day l of menses, replaced weekly for three weeks, and week four 
is patch free. Each patch should be placed at a different site. 
Using the contraceptive patch does not require direct genital contact or 
daily compliance that makes this contraceptive method popular with many 
adolescent females (105). Some may find that using the patch is more 
convenient than daily pill dosing as well as more user controlled and more 
readily reversible than Depo-Provera. ln addition, for those who have 
difficulty swallowing pills or gastrointestinal disturbances with OCPs, the 
patch may be a good alternative. There are no hormonal peaks and 
troughs as noted with OCPs, and cycle control as well as ovulation 
suppression is similar to Ortho-Cyclen (98-106).  
As noted, the adverse effects of the patch include potential site 
reactions (l.9%), a transient increase in breast tenderness, and also an 
increase in dysmenorrhea (94,103,107,108). Breast symptoms may 
increase with use of the patch and severity ranges from  mild to moderate. 
Cardiovascular side effects may be increased due to increased hormone 
levels (109,110). Obesity (i.e., weight > 90 kg) results in reduced 
contraceptive efficacy, but still higher than tbat noted with barrier 
contraceptives (58,59,98). Dermatitis may occur with the patch and those 
with exfoliative skin diseases or history of skin allergies may not be 
appropriate for the patch. Break-through bleeding and/or spotting may be 
more prevalent in menstrual cycles 1 and 2, than noted with OCPs. The 
incidence of nausea, emotional lability, and headaches are similar to that 
noted with OCPs. The patch produces a similar lipid profile, as noted with 
other OCPs containing EE and norgestimate (111). 
Pregnancy rates in adult women are similar when comparing the 
OCP and the patch, with pregnancy rates of 0.7 -1.24 per 100 women-
years reported with the patch versus 2.18 for OCPs (98-104). Adequate 
steroid levels are maintained for two days past the manufacturer's 
recommended 7-day application. The efficacy is similar with various 
application  sites.  This  rate  is  not  affected  by  warm  humid  climates, 
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vigorous exercise or exposure to saunas or water baths. Table 19 notes 
reasons for contraceptive failure with patch technology. 
Table 19. Causes of contraceptive failure with patch technology 
1. Keeping the patch on for over 7 days
2. Detachment of the patch  
3. Failure to begin a new patch after 7 days being off the patch  
Of the 15 pregnancies reported during clinical trials of the patch. 5 
were in women who weighed over 90 kg (198 pounds) (2,62). This 
finding led to a warning from the manufacturer that the patch may not be 
as effective in obese women. However, there has been little research on 
the efficacy of other hormonal contraceptives in obese females, so this 
finding may not be limited to the patch. Of over 70,000 patches that were 
used in adult females during clinical trials, only 4.7% were replaced 
because they fell off (1.8%) or were partially detached (2.9%) (62). 
However, one study of adolescents ages 15 to 18 noted a complete or 
partial detachment rate of 35.5% (62). If the patch is off after 24 hours, 
there is a need for back-up contraception for the next 7 days.
PROGESTIN-ONLY PILLS (POPS; MINI·PILLS) 
Contraceptive mechanisms of progestin-only pills (POPs) include 
thickening of the cervical mucus and endometrial involution.  Ovulation 
is not reliably inhibited and pregnancy rates can be 1 to 3 pregnancies 
per 100,000 (1,2,4,112-114). Progestins used in POPs include 0.35 mg of 
norethindrone (Micronor; Nor-Q.D) and 0.075 mg of norgestrel 
(Ovrette). POPs are recommended by some clinicians when estrogen is 
contraindicated (e.g., patients who have severe hypertension or coronary 
heart disease). POPs are generally safe for most cardiovascular disorders 
including cyanosis and atrial or ventricular arrhythmias. Common side 
effects of POPs include irregular uterine bleeding and amenorrhea; 
because of the irregular bleeding that POPs can induce, the mini-pill 
should be avoided in those with coagulation disorders (1,2,4,31). 
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POPs should not be used by females who have a history of ectopic 
pregnancy and taking medications such as anticonvulsants, griseofulvin, 
and rifampin. POPs are not contraindicated in females with obesity;  there 
is no increase in VT in obese females on progestin-only pills (58-60). 
POPs should be avoided if the adolescent has a history of an ectopic 
pregnancy and irregular menses, if she is clearly a candidate for methods 
with increased efficacy over mini-pills and if she is unlikely to be 
compliant with pills. A barrier method (e.g., condoms with diaphragm or 
with vaginal contraceptives) can be added to improve the overall 
contraceptive efficacy of the mini-pill.  
EMERGENCY CONTRACEPTIVES (ECs) 
Emergency contraceptives (Post-coital contraception) are among the 
most controversial and under prescribed contraceptive methods (see table 
20)(115-121). A number of mechanism are noted in pregnancy 
prevention including delay of ovum maturation, interference with corpus 
luteum function, thickening of cervical mucus, and others; thus, EC 
methods interfere with ovulation or implantation (if the egg is 
fertilized)(l19,122). Whenever adolescents seek EC, they should be 
counseled regarding effective contraceptive methods. A variety of OCPs 
can be taken after coital activity to prevent pregnancy, including Ovral 
(two pills followed in 12 hours by two more pills) and various brands 
which require four pills followed by four pills in 12 hours: Lo-Ovral, 
Levien and Nordette. In 1998, the FDA approved of the Preven 
Emergency Kit as an EC, based on the EC method described by Albert 
Yuzpe in 1974 using two pills (with ethinyl estradiol and levonorgestrel) 
followed in 12 hours by two more pills.
In 1999. the FDA approved of Plan B, a progestin-only EC method 
that consists of two tables of 0.75 mg of levonorgestrel (Levonelle). The 
first tablet of Plan B is taken immediately after unprotected coitus and 
the second tablet is taken 12 hours later; studies have shown that Plan B 
is equally effective when both pills are taken at the same time, as soon as 
possible after coitus (115). Because Plan B contains no estrogen, nausea 
and vomiting is uncommon and there is no need to obtain a pregnancy 
test before administration.  Thus,  Plan  B  may  be  better tolerated than 
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other ECs that contain estrogen (115). Although initially approved for 
use within three days of coitus, more recent studies have shown that Plan 
B may be effective in pregnancy prevention if taken up to five days after 
unprotected coitus (115-120). The expected pregnancy rate of 8% from 
an episode of unprotected coitus in the second or third week of the 
menstrual cycle is reduced to < 1 % with Plan B use (115-120). If ECs 
were more widely available, they could prevent 1.7 million unintended 
pregnancies and reduce abortions by 50% (116,120).  
Table 20. Emergency contraceptives 
• Ovral®: 2 tablets followed by 2 tablets in 12 hours 
• Lo/Ovral®, Nordette® or Levlen® : 4 labs and 4 more in 12 hours 
• TriPhasil® or Tri-Levlen® (yellow tabs only): 4 tabs, and 4 more in 12 
hours  
• Ovrette®: 20 tabs and 20 more in 12 hours 
• Preven® Emergency Contraceptive Kit 
• Plan B®: Levonorgestrel: 0.75 mg followed by 0.75 mg in 12 hours  
EC is very effective in preventing pregnancy, yet is not well-known 
among adolescents and college students. Adolescents should be clearly 
taught that emergency contraceptives can be used in va1ious situations, as 
listed in table 21 (118,123). Without proper instructions, youth do not 
use ECs effectively. Providing the emergency contraceptive for the 
patient to take home before it is needed may improve efficacy (119). 
Table 22 lists barriers to the use of ECs. An EC hot line is available in 
America (011-1-888-668-2528 or 011-1-888-NOT-2-LATE); there is 
also a web site: http://opr.princeton.edu/ec/.  
Table 21. Indications for the use of emergency contraception 
Having unplanned sex without protection 
Condom slipping/breaking  
Dislodgment of a diaphragm, cervical cap, IUD 
Missing more than 2 oral contraceptives in a row 
Being over 14 weeks from the last Depo-Provera® injection. 
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Table 22. Reasons for failure to use emergency contraception 
1. Religious/cultural pressures from the family and others 
2. Inability to pay for the services needed to obtain contraceptives 
3. Fear of the absence of confidentiality 
4. Fear of contraceptive side-effects 
5. Failure of health care providers to educate students about ECs
6. Failure of health care providers 10 prescribe ECs
7. Fear of liability
8. Fear it will undermine the youth's use of more efficacious
contraception  
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A copper-containing IUD can be used for EC by inserting it up to 
five days after unprotected sex anywhere in the cycle or up to five days 
after post expected ovulation in a female with regular cycle, which 
inhibits fertilization. It can remain in situ for long term contraception if  
desired. Mirena IUS (Intrauterine System) should not be used for 
emergency contraception (124). Contraindications to emergency 
contraception include existing pregnancy, known acute porphyria, and 
current warfarin treatment; in the latter situation, anticoagulation may be 
altered and then coagulation monitoring is necessary (124).  
Abstinence is recommended for two weeks after EC administration, 
while regular contraceptive methods should be started right away, with 
the exception of Depo-Provera which is best to be delayed for two weeks 
until pregnancy is ruled out. Pregnancy and sexually transmitted disease 
testing is recommended two weeks after E C  administration. Menstruation 
usually returns within seven days of the anticipated day. Providing E C  
information does not lead to youth to unprotected sex habits or decrease 
the use of regular contraceptive methods (123). 
Vaginal ring 
The NuvaRing is a soft, flexible, transparent vaginal ring made of an 
ethylene vinyl  acetate  copolymer.  It has an outer diameter of 54 mm and  
a cross-section of 4 mm (124). There are two steroid reservoir cores in 
the ring  that provide a daily  hormonal release of 15 mcg of ethinyl 
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estradiol CEE) and 120 mcg of etonogestrel (an active metabolite of 
desogestrel) (106,107). Etonogestrel implants with depot testosterone is 
under study as a long-acting male contraceptive (125).   
The NuvaRing provides hormone bio-availability comparable to an 
oral contraceptive, such as Desogen or Ortho-Cept. It is inserted by the 
female and removed after three weeks. After one week, a new ring is 
inserted for the next month. If the ring is expelled, it is washed and 
reinserted; if it is out over three hours, a back-up contraceptive method is 
recommended until the ring is back in place for seven days in a row. This 
contraceptive method is popular with college students who are 
comfortable with their bodies and accept this form of contraceptive 
technology. Patients should be educated that the ring does not prevent 
STDs, but provides contraceptive efficacy similar to combined oral 
contraceptive pills (126, 127). It can be used successfully by adolescent 
females who are educated about their bodies and this contraceptive 
method (31,128). 
Advantages of the intravaginal ring are listed in table 23 (126-131). 
Studies have shown that this contraceptive method is well-accepted by 
adult women and their partners (132-134). Side effects include prolonged 
menstrual bleeding lasting > 7 days in 25% of cycles, vaginal discomfort, 
vaginitis, and foreign body sensation. The other side effects noted in 
those using the NuvaRing are similar to OCP users, including an 
increased risk of thrombosis. There is usually less irregular bleeding than 
seen with OCPs. Obesity itself does not affect the contraceptive efficacy, 
though extremely obese females may have trouble inserting the ring. As 
ovulation returns during the first cycle after stopping ring use, there is the 
possibility of pregnancy immediately after discontinuing use of the ring 
(135). 
Table 23. Advantages of the Nuva ring 
Good contraceptive efficacy 
Continuous hormone release 
Gastrointestinal absorption not required 
Easily inserted and remove by the wearer 
Rapid return to ovulation after stopping 
Confidential method 
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VAGINAL BARRIER CONTRACEPTIVES 
Barrier contraceptives are listed in table 24 and are potentially good 
contraceptive methods for those who are highly motivated to avoid 
pregnancy, are comfortable with their bodies, and can use these methods 
correctly with each act of coitus (1,2,136). Some adolescents are well 
motivated and may choose these techniques over others discussed in this 
article. 
Table 24. Vaginal barrier contraceptives 
Diaphragm 
Cervical cap (Prentif) 
Vaginal contraceptive sponge (Today) 
Vaginal spermicides 
Female condom (Reality)  
Male condom 
Diaphragm and vaginal spermicides 
Table 25 outlines types of diaphragms that are available and table 26 lists 
contraindications to diaphragm use. Health care clinicians can learn how 
to fit diaphragms, providing the female with the correct size and 
instructions on how to successfully use this classic barrier method 
(l37J.The diaphragm is used with vaginal cream or foam, and can be 
used in conjunction with the condom for increased contraceptive 
efficacy, as well as increased protection from STDs. Vaginal 
contraceptives or spermicides include foams, creams, jellies, 
suppositories, and a film; Table 27 lists advantages of vaginal 
contraceptives (138-141). Side effects of these agents include vaginal 
odor and rarely allergic reactions (138). The diaphragm has been 
associated with an increased risk of urinary tract infections in some 
women, such as those with diabetes mellitus. Rarely, toxic shock 
syndrome has occurred in women using a vaginal diaphragm and this 
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method is contraindicated in women who have a past history of toxic 
shock syndrome.  
Table 25. Diaphragm types 
Coil-spring diaphragm (suited for general use) 
A metal wire is inserted in the rim; the wire is round and spiral-coiled; 
folds in one plane.  
Flat-spring diaphragm (Mensinga) (suited for anteverted uterus and/or 
a cervix which is long and posteriorly pointed) 
It is similar to the coil-spring type but is firmer. 
Matrisalus diaphragm (Bowbent) (Suited for those with a cystocele or 
vaginal-wall relaxation) 
Contains a steel band which is strong and flat; the band is curved and 
placed in the rim.
Arching-spring diaphragm (Findley) (Suited for those with poor muscle tone 
or have a 
cervix which is pointed posteriorly)  
This diaphragm has a double metal spring rim; an arc is formed when 
the rim is compressed. 
Table 26. Contraindications to the use of the diaphragm 
Allergy to rubber or  spermicides 
Anteversion (severe; forward tilting of uterus) 
Complete uterine prolapse 
Perineal tears 
Retroversion (severe; backward tilting of uterus) 
Short anterior vaginal wall 
Vesicovaginal (or rectovaginal) fistulas 
Toxic Shock Syndrome 
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Table 27. Vaginal contraceptive advantages 
• Allows the pair to share contraceptive responsibility when used 
with a condom 
• Can reduce dyspareunia if present (vaginal lubricant)
• Cost is minimal 
• Prescription is not needed 
• Provide effective contraception, especially if used in conjunction 
with condom or diaphragm 
• Side effects are few
• Useful for young women with only occasional coitus  
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Cervical cap 
The FDA approved the cervical cap (Prentif cavity-rim cervical cap) in 
1988, since it has similar contraceptive efficacy as other barrier 
contraceptives (1,2). This is a small, latex cap (with spermicide added 
inside) that is about half the size of a diaphragm; the cap fits around the 
cervix by suction. Four cervical cap sizes are available, 25% of females 
cannot be fitted, and some females find it difficult to insert the cap. 
Cervical cytology screening should be done before or at the time of 
fitting the cervical cap, since cervical dysplasia has been noted in some 
females using a cap; the screening is also to be done 3 months after the 
fitting. Cervical laceration, cervical scarring, and a history of toxic shock 
syndrome are contraindications to using cervical caps.  
Vaginal contraceptive sponge (Today) 
This is an over-the-counter. disposable, polyurethane sponge with a 
concave shape; it can be inserted up to two days before coitus and left in 
place 6 to 24 hours afterward (1,2). Vaginal malodor, vulvar rash, 
pruritus, candidiasis, and increased risk for urinary tract infection as well 
as toxic shock syndrome may develop. Contraceptive efficacy is similar 
to other barrier contraceptives. It was first introduced to the United States 
market in 1983, removed in 1994, and again became available in 2005. 
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Female condom 
The female condom is an over-the-counter, polyurethane bag or sheath 
that is placed in the vagina prior to coitus [1,142, 143]. It was FDA 
approved as a contraceptive agent in 1993 and in 2005 was made of 
nitrile and called FC2 with introduction to the US marker in 2007. It is 
not used with a male condom. The female condom offers some STD 
protection and provides contraceptive efficacy similar to other barrier 
contraceptives. Negative aspects of using the female condom include 
discomfort from inner ring insertion and distracting noise during coitus. 
Male condom  
Male condoms are recommended to reduce the risk of sexually 
transmitted diseases (STDs) as well as to prevent pregnancy (144-153). 
They do not eliminate the risk of STDs and are less effective in 
preventing the transmission of human papillomavirus (HPV) because of 
the potential wide spread presence of the HPV infection; condoms can 
stimulate regression of cervical intraepithelial neoplasia (CIN) and HPV 
clearance (1,2,150, 151). The contraceptive effectiveness of condoms is 
equivalent to other barrier contraceptives, if used correctly with each 
coital act. Advantages of condoms are listed in table 28 while reasons for 
not using condoms or inconsistent condom use are listed in table 29 
(144-147). 
The latex condom is preferred, since it is more effective at STD 
prevention (especially for viral STDs) and has much lower rates of 
slippage or breakage than noted with the Kraton polyurethane condom 
and lamb cecum condoms; many different kinds of condoms are 
available. Latex condoms are associated with increased breakage rates 
when exposed to high temperatures and/or ultraviolet light; they are also 
weakened by oil-based lubricants. Latex sensitivities can develop in 7% 
of the general population and 17-25% of health care workers (148). 
Health care professionals should present the subject of condoms in a 
positive, not negative light. Comprehensive education is needed for 
proper use, as well as role-play scenarios for convincing the partner to 
use condoms.  Adolescents  often  do  not  use  the  condom  and need 
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clinicians to discuss negotiation skills regarding male partner's 
reluctance (often) to use condoms and encouragement in this regard 
(1,27,149). 
Table 28. Advantages of the condom as a contraceptive 
• Allows male to actively take p:art and share in the contraception of 
the pair 
• Effective contraceptive agent
• Many types available
• May decrease dyspareunia
• Minimal side effects
• Available without prescription
• Decreases risk of sexually transmitted diseases 
Table 29. Reasons given for not using condoms as contraceptives 
• Condom may rupture 
• Cost
• Disrupts foreplay
• Failure of clinicians to recommend condoms 
• Failure of pharmacists to make condoms easily available
• Proper technique needed each time 
• Reduced penile sensation during coitus
• Refusal of contraceptive responsibility
• Religious beliefs
• Stigma of using a method which is associated with promiscuity
and STDs
• Prefers other contraceptive method 
• Feel they are low risk for STD acquisition
• Criticism of some that condoms are not 1 00% effective in STD 
protection and thus,
• should not be used
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INJECTABLE CONTRACEPTIVES 
Medroxy-progesterone acetate (Depo-Provera; PMPA) is the main 
injectable contraceptive available in the United States (1,2,58,154-158).     
It inhibits ovulation and induces a thin endometrium as well as thick 
cervical mucus. Depo-Provera is given as an intramuscular dose of 150 
mg every three months and has a pregnancy failure rate of only 0.3%. It 
was approved for the treatment of endometriosis in 1960 and approved to 
provide contraception in many countries in 1980 (156). FDA approval 
was delayed until 1992  because of concern over possible increased risk 
of breast cancer and mutagenic properties even though this contraceptive 
had been used for many years in other countries; none of these concerns 
have ever been substantiated. Because Depo-Provera does not contain 
estrogen, it can be used by women for whom estrogen is contraindicated. 
A partial list of adverse effects of Depo·Provera are listed in table 30. 
There is no decreased contraceptive efficacy noted in obese females 
versus normal weight females, though additional weight gain can occur 
in some females on this contraceptive (see table 30) (59). 
Table 30. Partial list: Side-effects of Depo-Provera 
Acne 
Amenorrhea 
Behavioral changes (depression, anxiety, irritability) 
Breast tenderness 
Decreased bone density 
Dizziness  
Fatigue 
Glucose intolerance 
Hair loss 
Irregular menstrual bleeding 
Nausea 
Weight gain 
• 
• 
• 
• 
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Bone loss is noted in adolescents on this agent and thus, it should be 
avoided in those at risk for low bone density, such as adolescents who 
have chronic renal disease, anorexia nervosa, and possibly those who are 
wheel-chair bound (1,2,4,62, 154). Depo·Provera users often stop 
menstruating, especially with prolonged use. Benefits of this 
contraceptive method include reduced incidence of dysmenorrhea and 
premenstrual tension syndrome. It may reduce seizure activity in some 
women who have epilepsy. Fertility can be delayed for one year or more 
after disconti11uation due to prolonged effect of contraceptive efficacy. 
Individuals with psychosis and mental retardation who are at risk for 
pregnancy have been prescribed this injectable contraceptive (89. 90).  
In 2000, the FDA gave approval to another injectable contraceptive, 
Lunelle (5 mg estradiol cypiona1e and 25 mg medroxyprogesterone 
acetate [MPA/E2C]); it is given intramuscularly every month (every 28- 
30 days) and has very high contraceptive efficacy. It is available as 
Cyclo-Provera and as Cyclofem in other countries. Because this 
injectable contains estrogen, amenorrhea and dysfunctional uterine 
bleeding (DUB) are less common than noted with Depo-Provera. The 
mean cycle length is 28 days and there is a predicable bleeding-free 
interval and less breakthrough bleeding than is noted with OCPs. There 
also is a rapid return to fertility after discontinuation. The company that 
manufactures this product recalled it in 2002, because of concerns about 
the amount of hormones in it. Another progestin-estrogen product that is 
injectable and available outside the United States is Mesigyna (with 50 
mg of norethindrone and 5 mg of estradiol valerate) (154,155). 
INTRAUTERINE DEVICES (IUDS) 
There are three IUDs which currently are used in the United States: 
Progestasert IUD, the ParaGard (Copper T380A) and the Mirena IUD 
(1,2,31,157,159,169). Progestasert IUD was first made available in 1976; 
it is replaced annually and has an expulsion rate of 2.7%. Paragard was 
introduced in 1983 and has a lower failure rate than the Progestasert 
IUD; it is replaced every 8 to 10 years and has a reported expulsion rate 
of 5%. Paragard may help protect adult women against endometrial 
carcinoma.  There  are various other copper  IUDs  in the world market but 
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only ParaGard is available in the United States. The IUD is used by 12% 
of adult women using contraception in the world versus 1% in the United 
States (160). 
The IUD has been linked in the past with inducing increased rates of 
pelvic inflammatory disease (PID), even though careful analysis notes 
that the IUD-induced risk is minimal (37). However, litigious concerns 
have resulted in a situation in which most clinicians in the United States 
will not insert an IUD in a female unless she is at a minimal age (often 
21 years of age), is in a mutually monogamous relationship, has no 
history of PID or ectopic pregnancy, and has demonstrated her fertility. 
The Mirena IUD (levonorgestrel-containiog IUD; LNG-IUD) is a 
second generation of steroid-releasing IUDs; it has a 32 by 32 mm Nova 
T-shaped polyethylene-barium sulfate frame (11/4" tall and wide, made of 
plastic) with a rervoir around the vertical stem containing silicone and 
52 mg of levonorgestrel (161). Two threads for removal are attached to 
the end of the stem. It is packaged in a sterile state inside an insertion 
device that is disposable. 
This IUD releases 20 mcg of levonorgestrel per 24 hours over the 
first five years of use; the levonorgestrel released decreases to 10 µg/day 
after five years. Concentrations in the plasma stabilize to 150-200 pg/ml, 
less than noted with oral contraceptives or Norplant. Mirena has been 
available in Europe for over 10 years and has been used by over two 
million women worldwide (161). The Mirena IUD was approved by the 
FDA in 2001 for five years use in the United States, though it is used in 
Europe for seven to 10 years before replacement is recommended. It is a 
highly effective contraceptive, with a failure rate of 0.2% in the first year 
and 0.7% at five years (161-164). It is inserted before day seven of the 
cycle and is not effective if inserted post-coitally. A newer insertion 
device allows easy insertion with minimal uterine perforation risks. It 
exerts a local effect on the endometrium, as well as the cervical mucus, 
and can initially lead to systemic effects (165). 
Table 31 lists the contraceptive mechanism of IUDs ( 166). Ovulation 
can continue and amenorrhea may develop because of endometrial 
thinning. Table 32 lists the side effects of the Mirena IUD. The most 
common side effect is menstrual bleeding; there is increased bleeding 
and spotting during the first 3 to 6 months after insertion, but this usually 
decreases  thereafter.  This  IUD  has been used to reduce heavy menstrual 
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bleeding in adult females because up to 90% of menstrual blood loss 
eventually may be decreased (167-170). The use of an IUD in females 
with mental retardation has been identified (89,90). Table 33 lists the 
benefits of the Mirena IUD (169). Contraindications to Mirena use 
include active pelvic inflammatory disease, prosthetic heart valves, 
history o f  subacute bacterial endocarditis, and distorted uterine cavity. 
Obese females have an increased incidence of dysfunctional uterine 
bleeding and endometrial hyperplasia, making the Mirena IUD a good 
contraceptive choice for obese females needing contraception; there is no 
decreased contraceptive efficacy due to obesity (58,59). 
Table 31. IUD contraceptive mechanisms 
I. Prevents fertilization
2. Interferes with ovum development 
3. Interferes with sperm movement and ability to penetrate ovum 
4. Inhibits sperm survival
5. Helps prevent egg release
6. Thickens cervical mucus  
Table 32.  Mirena side effects (160) 
Common 
Initial increased menstrual bleeding 
Abdominal pain 
Uncommon 
Acne/other skin problems 
Back pain 
Breast tenderness 
Headache
Nausea 
Mood changes 
Rare 
Hypersensitivity reaction 
IUD becomes embedded in myometrium 
Perforation of uterus or cervix
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IUD inserted during pregnancy (increases pregnancy complications: 
Miscarriage, sepsis, premature labor, premature delivery) 
Development of intrauterine pregnancy after insertion; must remove 
IUD 
Table 33. Benefits of Mirena IUD 
1.        Effective contraception
2. Eventual reduction in menstrual flow (90%)
3. Frequent amenorrhea 
4. Decreased dysmenorrhea
5. Decreased premenstrual syndrome 
6. Very low rates of infectious complications
7. May decrease PID incidence in the long run 
8. Decreases ectopic pregnancy (2/10,000)
9. Avoids use of estrogen
10. No significantly increased pregnancy risk if on anti-epileptic or  
   other Enzyme-inducing medications 
11.     Rapid return to fertility (80% within one year of removal)
IMPLANTS 
Norplant is a long-acting, levonorgestrel-containing contraceptive 
designed to be implanted subcutaneously in the upper arm (1,2). Each of 
the six matchstick-sized capsules is 34 mm long and 2.4 mm in diameter 
and contains 36 mg of levonorgestrel. Contraindications to its use include 
active thrombophlebitic or thromboembolic disorder, undiagnosed or 
abnormal genital bleeding, known or suspected pregnancy, acute liver 
disease (including. benign or malignant liver tumors), and known or 
suspected carcinoma of the breast. It was withdrawn from the United 
States market in 2000. 
Implanon contains one rod (vinyl ethylene acetate polymer) that 
contains etonogestrel, while the Jadelle implant (Norplant II) has two 
silastic rods with levonorgestrel (15,171,172). These two implants are 
FDA-approved  for  three  years.    There  is  no  decreased  efficacy  with 
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obesity, though some have lower etonogestrel levels (59). Some weight 
gain may be noted with both implants. 
STERILIZATION 
Sterilization (female sterilization. vasectomy [males]) is not normally 
recommended for adolescents, but has been suggested for youth with 
such issues as intellectual disability/mental retardation or schizophrenia. 
However, it remains a controversial issue in the United States and is 
generally only appropriate for some adult females (173,174). 
NATURAL FAMILY PLANNING 
Natural family planning (fertility awareness; physiologic methods) is the 
method based on recognition of ovulation timing. Usually, there is a 
combination of daily temperature recording, cervical mucus observation, 
and other symptoms (175). General information about the calendar 
method is good education for youth and can help them use other 
contraceptives more effectively; however. adolescents are usually not 
motivated enough to correctly use natural family planning and it has a 
high failure rate in youth (176). 
COITUS INTERRUPTUS 
Coitus interruptus is a method used by many youth and is one of the 
oldest contraceptive methods. However, it is not a recommended 
contraceptive method for adolescents because of its high failure rate- 
19% per annum (1,2). 
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CONCLUSIONS 
Contraception is an important concept for sexually active adolescent 
females to understand who do not wish to become pregnant. This chapter 
has reviewed important, effective, and safe contracep1ive methods that 
can be used by female youth. Promotion of sexual responsibility should 
be the charge of health professionals caring for adolescents and young 
adults. The framework of sexual responsibility includes prevention of 
unwanted pregnancy and S1Ds. The clinician should provide 
contraceptive advice chat elicits important pertinent information such as 
age and sex of her partner as well as last unprotected sex and menstrual 
period. Education can be given regarding appropriate information about 
pregnancy and STD risk as well as contraindications to contraceptive 
methods (17,177,178). 
Youth who have chronic illness and are sexually active should also 
be provided with safe, effective contraception, as reviewed in this 
chapter. Though abstinence is a highly recommended method of 
concraccption, coitus interuptus and natural family methods are not, 
because of their high failure rates. Care must be utilized in prescribing an 
IUD  in the  adolescent or college student, because of the litigious  overlay 
of concern for pelvic inflammatory disease, as reviewed in the IUD 
section of this discussion. Finally, sterilization is a method of 
contraception normally not recommended for youth. 
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